Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, explains that although hematopoietic stem cell transplantation (HSCT) is a curative approach for hematological malignancies, some patients will relapse or die due to complications. There is a need for a better identification of relevant prognostic factors to help personalize treatments and procedures, where Big Data analysis can play a key role. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

свернуть